Severe Sepsis Clinical Trial
Official title:
Descriptive Study of the Evolution in Proportion of Regulatory B Lymphocytes in Patients Hospitalized in Intensive Care for Severe Sepsis
Severe sepsis and septic shock are the most severe forms of sepsis (which associates a
systemic inflammatory response with infection). These are serious pathologies with a
lethality estimated at almost 40% at 28 days (after the onset of sepsis).
After a first pro-inflammatory phase, a second compensatory phase called Compensatory
Anti-Inflammatory Response Syndrome (CARS) takes place quickly. Patients then show signs of
immunosuppression and profound alterations in immune functions. It is during this phase that
the vast majority of deaths occur, far from the onset of the shock, which is related to the
inability of the immune system to eliminate the initial infectious agent and / or a greater
susceptibility Important to develop secondary infections (nosocomial infection, latent virus
reactivation ...).
The CARS phase has been the subject of studies focusing on measuring the plasma
concentration of anti-inflammatory cytokines (such as Interleukin (IL) -10), the percentage
of regulatory T lymphocytes (Treg), Or the percentage of monocytic expression of HLA-DR in
septic patients.
The investigator proposes to carry out the first study on a newly described regulatory
lymphocytic subpopulation: regulatory B lymphocytes (Breg) from a quantitative and
functional point of view in severe septic states.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
| Completed |
NCT02539147 -
Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis
|
N/A | |
| Completed |
NCT01932814 -
Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?
|
N/A | |
| Completed |
NCT01929772 -
German Lactat Clearance in Severe Sepsis
|
N/A | |
| Completed |
NCT01449721 -
Preemptive Resuscitation for Eradication of Septic Shock
|
N/A | |
| Active, not recruiting |
NCT01162109 -
Zinc Therapy in Critical Illness
|
Phase 1 | |
| Not yet recruiting |
NCT01211899 -
4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock
|
N/A | |
| Completed |
NCT00934011 -
Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections
|
N/A | |
| Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
| Completed |
NCT00463645 -
Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients
|
N/A | |
| Completed |
NCT02361528 -
GM-CSF to Decrease ICU Acquired Infections
|
Phase 3 | |
| Completed |
NCT02734550 -
(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis
|
N/A | |
| Completed |
NCT02973243 -
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
|
N/A | |
| Terminated |
NCT03895853 -
Early Metabolic Resuscitation for Septic Shock
|
Phase 2 | |
| Completed |
NCT01945983 -
Early Use of Norepinephrine in Septic Shock Resuscitation
|
N/A | |
| Completed |
NCT01598831 -
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
|
Phase 3 | |
| Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A |